Profile data is unavailable for this security.
About the company
Citius Oncology, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on oncology products. Its LYMPHIR (denileukin diftitox-cxdl) is approved by United States Food and Drug Administration for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (a rare form of non-Hodgkin lymphoma) after at least one prior systemic therapy. LYMPHIR is a specially engineered IL-2- diphtheria toxin fusion protein made using recombinant DNA technology. It works by targeting cells that have IL-2 receptors with a toxin derived from diphtheria bacteria. It directly kills tumor cells by binding to the IL-2 receptors and internalizing the diphtheria toxin directly into the tumor cells, causing them to die. It boosts the body's immune response by reducing the number of regulatory T-cells (Tregs) that suppress the immune system, thereby enhancing the body's ability to fight the tumor.
- Revenue in USD (TTM)0.00
- Net income in USD1.93m
- Incorporated2024
- Employees--
- LocationCitius Oncology Inc420 Lexington Ave, Suite 2446NEW YORK 10017United StatesUSA
- Phone+1 (347) 627-0058
- Fax+1 (302) 531-3150
- Websitehttps://www.tenxkeane.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Precision BioSciences Inc | 75.10m | 11.48m | 55.69m | 108.00 | 9.50 | 0.8372 | 3.55 | 0.7416 | 0.7641 | 0.0524 | 12.85 | 8.67 | 0.4729 | -- | 29.70 | 688,954.10 | 7.23 | -35.35 | 9.00 | -44.22 | -- | -- | 15.28 | -147.50 | -- | -- | 0.2557 | -- | 94.15 | 34.96 | 41.67 | -- | -32.01 | -- |
| Dyadic International Inc | 3.36m | -6.33m | 56.89m | 7.00 | -- | 16.74 | -- | 16.91 | -0.2183 | -0.2183 | 0.1156 | 0.1153 | 0.3354 | -- | 8.73 | 480,651.40 | -63.11 | -36.82 | -76.60 | -39.85 | 64.57 | 22.47 | -188.14 | -410.16 | -- | -- | 0.6069 | -- | -1.07 | 17.48 | 30.20 | -- | -- | -- |
| X4 Pharmaceuticals Inc | 1.12m | -16.76m | 56.95m | 93.00 | -- | 0.9553 | -- | 50.71 | -0.0853 | -0.0853 | 0.0056 | 0.3538 | 0.0064 | -- | 1.53 | 12,075.27 | -9.54 | -61.53 | -11.29 | -69.20 | 55.92 | -- | -1,492.34 | -13,288.93 | 4.80 | -- | 0.5579 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Mural Oncology PLC | 0.00 | -153.78m | 57.15m | 109.00 | -- | 0.3278 | -- | -- | -9.14 | -9.14 | 0.00 | 10.22 | 0.00 | -- | -- | 0.00 | -131.73 | -- | -168.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -21.24m | 59.80m | 31.00 | -- | 1.26 | -- | -- | -1.33 | -1.33 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -54.12 | -58.43 | -57.23 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
| Bioqual Inc | -100.00bn | -100.00bn | 60.37m | 108.00 | -- | 1.63 | -- | -- | -- | -- | -- | 41.34 | -- | -- | -- | -- | -- | 8.14 | -- | 9.52 | -- | 19.36 | -- | 7.13 | -- | -- | 0.00 | 21.43 | -5.27 | 11.79 | -84.12 | -25.26 | 1.60 | 10.76 |
| Celularity Inc | 42.69m | -112.83m | 60.68m | 120.00 | -- | 2.18 | -- | 1.42 | -5.77 | -5.77 | 2.14 | 1.27 | 0.2236 | 3.92 | 4.65 | 355,750.00 | -59.09 | -19.19 | -90.61 | -20.99 | 60.24 | -- | -264.30 | -454.79 | 0.2182 | -11.18 | 0.5958 | -- | 26.68 | -- | -1,483.14 | -- | -- | -- |
| Citius Oncology Inc | 0.00 | 1.93m | 60.76m | -- | 3.52 | 0.1229 | 31.42 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
| Cue Biopharma Inc | 9.53m | -44.61m | 61.41m | 53.00 | -- | 2.42 | -- | 6.44 | -0.906 | -0.906 | 0.1925 | 0.4213 | 0.1677 | -- | 3.96 | 179,849.10 | -78.47 | -57.45 | -111.95 | -68.41 | -- | -- | -468.02 | -810.87 | -- | -- | 0.1726 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| Champions Oncology Inc | 51.66m | -3.40m | 61.85m | 210.00 | -- | -- | -- | 1.20 | -0.2541 | -0.2541 | 3.78 | -0.0244 | 1.88 | -- | 5.75 | 245,976.20 | -12.39 | -10.00 | -44.43 | -23.00 | 44.27 | 46.58 | -6.58 | -6.04 | -- | -- | 333.00 | -- | -6.90 | 13.13 | -36.38 | -- | 0.0479 | -- |
| Immuneering Corp | 0.00 | -58.07m | 62.27m | 66.00 | -- | 1.13 | -- | -- | -1.97 | -1.97 | 0.00 | 1.86 | 0.00 | -- | -- | 0.00 | -63.66 | -- | -68.36 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
| Spero Therapeutics Inc | 106.46m | 3.51m | 62.70m | 46.00 | 19.05 | 0.9618 | 17.48 | 0.589 | 0.0609 | 0.0609 | 1.97 | 1.21 | 0.8788 | -- | 3.78 | 2,314,239.00 | 2.90 | -35.52 | 4.19 | -41.75 | -- | -- | 3.30 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| RetinalGenix Technologies Inc | 0.00 | -4.04m | 62.99m | 0.00 | -- | -- | -- | -- | -0.2291 | -0.2291 | 0.00 | -0.101 | 0.00 | -- | -- | -- | -9,059.05 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -1,050.46 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
| Allovir Inc | 0.00 | -100.20m | 63.53m | 112.00 | -- | 0.5241 | -- | -- | -0.8755 | -0.8755 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -54.04 | -52.85 | -59.58 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
| Atara Biotherapeutics Inc | 100.44m | -133.16m | 64.96m | 159.00 | -- | -- | -- | 0.6467 | -26.44 | -26.44 | 18.00 | -15.77 | 0.606 | 1.69 | 134.10 | 446,395.60 | -80.34 | -70.20 | -276.19 | -86.94 | 82.70 | -- | -132.58 | -1,559.33 | 0.4993 | -46.83 | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
Data as of Nov 22 2024. Currency figures normalised to Citius Oncology Inc's reporting currency: US Dollar USD
0.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RiverNorth Capital Management LLCas of 30 Sep 2024 | 21.90k | 0.03% |
| Palmer Square Capital Management LLCas of 30 Jun 2024 | 18.55k | 0.03% |
| Yakira Capital Management, Inc.as of 30 Sep 2024 | 15.50k | 0.02% |
| Virtu Americas LLCas of 30 Sep 2024 | 10.29k | 0.01% |
| Arbor Point Advisors LLCas of 30 Sep 2024 | 5.13k | 0.01% |
| UBS Securities LLCas of 30 Sep 2024 | 1.63k | 0.00% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Sep 2024 | 350.00 | 0.00% |
| BofA Securities, Inc.as of 30 Sep 2024 | 160.00 | 0.00% |
| Tower Research Capital LLCas of 30 Sep 2024 | 41.00 | 0.00% |
| W.R. Berkley Corp. (Investment Portfolio)as of 30 Sep 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2024 - 11 Nov 2024Source: FactSet Research Systems Inc.
